In the next 5-8 years, it is a rapid growth period for drug development in China.
It was learned that the domestic CRO platform “Pharmaceutical Research Institute” announced the completion of the 300 million yuan C round of financing. This round of financing was led by Sequoia China and Zhongding Capital, Jingwei China, Yuanhao Capital, Yuansheng Capital and Investment, Huaxing Alpha as the exclusive financial advisor. The funds will be used for the development of technology supply products such as platform supply chain system construction, technology + data-driven business, enhance customer value experience, and continue to explore the needs of clinical research industry.
Besides the trillion-dollar drug market, clinical research is an indispensable part of the development of new drugs, and it has also spawned a market of 100 billion. It was summed up in Medical 2019 mid-term, CRO/CMO companies have ushered in a wave of financing this year, as of The number of financing events in June reached 16. In the near future, another preclinical CRO company “Bai Sai map” also received 543 million yuan on August 8 this year. D round of financing.
Sun Yanlin, CEO of Pharmaceutical Research Institute, pointed out that she believes that in the next 5-8 years is a rapid growth period for drug development in China.
“Pharmaceutical Research Institute” was established in December 2015 and is a company that continues to pay attention. According to previous report, it is a collaborative platform for clinical research services linking pharmaceutical companies, hospitals and R&D personnel. The way of sharing “human + data” and information management is to reduce costs and increase efficiency in the clinical trial phase of drug development. Many projects show that Pharmacy can shorten the development cycle of pharmaceutical companies by 20% and reduce research and development costs by 15%.
The main products include: clinical research research portal Trail.link, pharmaceutical research institute APP, inquiry medicine APP, drug research and development and public number of the research and development circle. At the same time, it provides CRO services such as medical writing, clinical auditing, and registration, and SMO services such as on-site management, subject management, and data entry, as well as center research and patients.Recruitment, data consulting and other services.
At present, the Trial.Link platform enables 180+ hospitals/institutions to enter, and 300+ pharmaceutical/sponsor access. The company’s full-platform users cover more than 95% of the pharmaceutical R&D industry’s practitioners. The service covers 800+ research hospitals, and the largest single project achieves collaborative coverage of 300 hospitals.
In terms of investment logic, the views of Zhu Yingchun, a partner of Zhongding Capital, and Yan Jia, the managing director of Sequoia China, can be refined into the following points:
-
Looking at the CEO industry development. The development of medical innovation technology, the influx of large-scale investment and the reform of the medical system will lead the CRO industry to a new round of rapid growth.
-
Looking at the standardization of 2B services. I believe that new technologies can drive 2B services to be standardized, systematic, and intelligent, making services as defined, operational, and data-driven as commodity SKUs
-
Looking at the Pharmacy team and business model. I believe that under the leadership of Sun Meilin’s management, the flexible human organization, technology and data empowerment of Pharmacy will bring faster service cycles, better supervision and lower development costs. And open up more experimental sites, it is expected to open up various participants in the industry chain and promote industry upgrading.